Loading
Invasive cribriform carcinoma is a rare, low-grade type of breast cancer whose cells grow in sieve-like nests, closely related to tubular carcinoma. In its pure form it has an excellent outlook, with no deaths from the cancer in the defining series, and it is treated like other hormone-driven breast cancer with the least treatment possible.
The WHO classification defines invasive cribriform carcinoma by invasive nests with sieve-like spaces making up over 90 percent of the tumour (classical form) or over 50 percent with a tubular component (Tan 2020). In the Edinburgh review of 1,003 carcinomas, 51 were predominantly cribriform; of the 35 classical cases none had died of the carcinoma 10 to 21 years later and 30 remained alive, while the 16 mixed cases with less differentiated areas did worse but still better than invasive carcinoma in general (Page 1983). In the George Washington series pure and predominant cribriform carcinomas metastasised to axillary nodes frequently but almost never to more than three nodes, were oestrogen-receptor positive in 100 percent and progesterone-receptor positive in 69 percent, and had five-year survival of 100 percent for pure or at least 50 percent cribriform tumours (Venable 1990).
How it differs from its parent: with tubular carcinoma it forms the low-grade luminal special types with near-normal survival; it must be distinguished from cribriform ductal carcinoma in situ, which often accompanies it, and from adenoid cystic carcinoma.
How common: about 5 percent showed a predominant pattern in the 1983 series, and pure cases are fewer (Page 1983); no modern population figure was found in the sources read.
Treatment: as HR-positive breast cancer following the parent page, with surgery, radiotherapy after breast conservation and endocrine therapy, and rarely chemotherapy; there is no trial in the type.
51 of 1,003 invasive breast carcinomas (5 percent) in the Edinburgh series showed a predominantly cribriform pattern, 35 of them classical (Page 1983); the pure form is rarer than that share suggests.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Basal-like 2 triple-negative breast cancer (BL2), Mesenchymal triple-negative breast cancer (M), Mesenchymal stem-like triple-negative breast cancer (MSL), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive breast carcinoma with medullary pattern (medullary carcinoma), Invasive micropapillary carcinoma of the breast, Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
Treated as HR-positive breast cancer with the least treatment the parent page allows.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Invasive cribriform carcinoma of the breast" OR ABSTRACT:"Invasive cribriform carcinoma of the breast" OR TITLE:"Invasive cribriform carcinoma" OR ABSTRACT:"Invasive cribriform carcinoma" OR TITLE:"Infiltrating cribriform carcinoma" OR ABSTRACT:"Infiltrating cribriform carcinoma" OR TITLE:"Cribriform breast cancer" OR ABSTRACT:"Cribriform breast cancer") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Invasive cribriform carcinoma of the breast, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
A swollen painful calf, or sudden breathlessness with chest pain; the tamoxifen boxed warning covers pulmonary embolism and stroke.
Possible QT prolongation. Check ECG and electrolytes; review other QT-prolonging drugs.
Blood clots in the leg veins or lungs. Cancer makes blood clot more easily and some treatments (IMiDs, anti-VEGF drugs, hormone therapy, central lines, surgery) add risk; clots are the second commonest cause of death in cancer patients after the cancer itself.
See all on the product pages:Tamoxifen·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Invasive cribriform carcinoma of the breast, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.